Fulcrum Therapeutics (FULC) Receivables - Accured (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Receivables - Accured data on file, last reported at $1.8 million in Q1 2026.

• Receivables - Accured for Q1 2026 came in at $1.8 million, up 13.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (up 13.7% YoY), and the FY2025 annual result was $1.1 million, down 14.13% from the prior year.
• Receivables - Accured rose to $1.8 million in Q1 2026 per FULC's latest filing, from $1.1 million in the prior quarter.
• Over five years, Receivables - Accured peaked at $1.8 million in Q1 2026 and troughed at $392000.0 in Q2 2022.
• A 5-year average of $1.1 million and a median of $1.2 million in 2023 frame the typical range for Receivables - Accured.
• The sharpest annual moves came in 2022 and 2025: Receivables - Accured soared 298.04% in 2022, then sank 40.66% in 2025.
• A 5-year view of Receivables - Accured shows it stood at $852000.0 in 2022, then jumped by 100.94% to $1.7 million in 2023, then declined by 27.22% to $1.2 million in 2024, then declined by 14.13% to $1.1 million in 2025, then surged by 65.98% to $1.8 million in 2026.
• Business Quant data shows FULC's Receivables - Accured at $1.8 million in Q1 2026, $1.1 million in Q4 2025, and $934000.0 in Q3 2025.